The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Szela Mary T since 2017.
This trader's CIK number is 1410289.
At the time of last reporting, Szela Mary T was the CEO and President of Trisalus Life Sciences, Inc.. (stock ticker symbol TLSI).
Also see all insider trading activities at Trisalus Life Sciences, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | CHRS | 0 | $0 | 54,997 | $966,737 | 54,997 | $456,860 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | TLSI | 30,487 | $124,996 | 0 | $0 | 0 | $0 |
| 2025 | TLSI | 19,582 | $102,053 | 0 | $0 | 0 | $0 |
| 2024 | TLSI | 19,815 | $99,808 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | NVLN | 0 | $0 | 0 | $0 | 6,632 | $0 |
1. Coherus Biosciences, Inc. (CHRS)
2. Trisalus Life Sciences, Inc. (TLSI)
3. Novelion Therapeutics Inc. (NVLN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-06-22 | CHRS | Sale | 54,997 | 17.58 | 966,737 |
| 2020-06-22 | CHRS | Option Ex | 54,997 | 8.31 | 456,860 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-02-23 | TLSI | Buy | 30,487 | 4.10 | 124,996 |
| 2025-01-29 | TLSI | Buy | 5,030 | 5.03 | 25,300 |
| 2025-01-30 | TLSI | Buy | 5,010 | 5.28 | 26,452 |
| 2025-01-27 | TLSI | Buy | 4,826 | 5.42 | 26,156 |
| 2025-01-28 | TLSI | Buy | 4,716 | 5.12 | 24,145 |
| 2024-09-13 | TLSI | Buy | 7,295 | 4.92 | 35,854 |
| 2024-09-12 | TLSI | Buy | 7,520 | 5.20 | 39,104 |
| 2024-09-10 | TLSI | Buy | 5,000 | 4.97 | 24,850 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-05-09 | NVLN | Option Ex | 6,632 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Szela Mary T (CEO and President of Trisalus Life Sciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.